Measuring Regeneration in Preclinical Research

Key Takeaways

Regeneration is not established by one marker: convincing evidence connects new tissue to restored cell identity, architecture, and function. [1] [2]
Histology, imaging, lineage tracing, molecular assays, and functional tests answer different questions and are strongest when their results converge. [3] [4]
Cell-cycle activity does not necessarily mean that new functional cells were produced; this distinction is especially important in tissues where cells can replicate DNA without completing division. [5]
Predefined outcomes, appropriate controls, randomization, blinding, sample-size justification, and transparent reporting affect how credible a regenerative claim is. [6] [7]

In preclinical research, “regeneration” can describe outcomes ranging from molecular activation to the replacement of a complex tissue. These are not equivalent endpoints. Regenerative capacity also varies across species, organs, injury types, and life stages, so measurement must be tied to a clearly defined biological question. [1] [2]

Who This Is Useful For

This page is useful for readers evaluating animal or laboratory studies that report tissue regrowth, increased proliferation, reduced scar, new cell formation, or functional recovery. It provides a framework for asking what was measured, what that measurement can establish, and what evidence remains missing.

What Counts as Regeneration?

A practical definition begins with replacement of tissue lost through injury or normal turnover. For a complex structure, however, replacement is not only a question of volume. The regenerated region must contain appropriate cell types arranged into useful tissue architecture, and it must contribute to the organ's function. Regeneration can therefore be complete, partial, or mixed with repair and fibrosis. [1] [2] [4]

The appropriate standard depends on the claim. A study asking whether a pathway activates after injury may reasonably use molecular endpoints. A study claiming organ regeneration requires broader evidence that distinguishes pathway activation from durable restoration. [1] [5]

Measurement Domains at a Glance

Domain	Typical Readouts	What They Support	What They Do Not Establish Alone
Structure	Histology, morphometry, micro-CT, MRI, scar or defect volume	Amount, location, and organization of newly formed tissue	Cellular origin or normal function. [4]
Cell production and identity	Cell-type markers, nucleotide labels, mitotic markers, clonal or lineage tracing	Which cells appear, cycle, divide, or contribute descendants	That every labelled cell matured or integrated correctly. [3] [5]
Molecular state	Gene expression, proteins, chromatin accessibility, signalling reporters	Activation of injury-responsive or regenerative programmes	Successful tissue replacement or recovery by itself. [1]
Function	Force, conduction, perfusion, locomotion, organ-specific physiological tests	Whether the treated system performs a relevant task	That native anatomy was restored or that recovery arose from regeneration. [8]
Durability and safety	Repeated follow-up, late histology, arrhythmia, overgrowth, ectopic tissue	Persistence and possible adverse consequences of the response	Generalizability beyond the tested model and follow-up period. [5] [7]

Start with the Claim and Primary Outcome

Measurement is clearest when the main question and primary outcome are specified before data collection. The primary outcome determines the central comparison and informs the sample-size calculation; additional outcomes can test mechanism or provide context, but they should not silently replace an unsuccessful primary endpoint. General preclinical design guidance treats this separation as part of controlling bias and avoiding selective interpretation. [6] [7]

The experimental unit must also be explicit. Multiple images, sections, cells, or limbs taken from one animal are repeated observations within that animal rather than automatically independent biological replicates. Reporting both the sampling hierarchy and the analysis method is necessary to judge the precision of an estimate. [6] [7]

Measuring Structural Replacement

Structural assays quantify such features as residual defect size, new tissue volume, tissue continuity, matrix composition, vascularization, or scar burden. Serial imaging can follow change within the same animal, whereas endpoint histology provides higher-resolution information about cells and matrix. In preclinical bone and cartilage research, these approaches are complementary because imaging, histology, and mechanical testing describe different properties of the repair tissue. [4]

More tissue is not necessarily more faithful tissue. A defect can fill with fibrotic matrix, immature tissue, or material that differs from the original organ. Structural evaluation therefore benefits from spatially defined sampling, validated segmentation or scoring, blinded assessment, and comparison with both injured and uninjured reference tissue. [2] [4] [6]

Determining Where New Cells Came From

Cell-type staining shows phenotype at the time of collection but usually does not reveal ancestry. Lineage tracing labels a defined starting population and follows inherited labels in its descendants, allowing researchers to test whether surviving mature cells, resident progenitors, or another source contributed to the regenerated tissue. [3]

Lineage evidence has its own assumptions. Promoter specificity, labelling efficiency, induction timing, reporter behaviour, and injury-induced changes in gene expression can all affect interpretation. Controls that characterize the labelled population before injury and detect background recombination are therefore part of the measurement, not merely technical details. [3]

Why Proliferation Is Not the Same as Regeneration

Markers such as Ki-67, EdU, BrdU, or phospho-histone H3 identify particular stages or products of the cell cycle. They do not all demonstrate completed cytokinesis. In adult cardiomyocytes, for example, DNA synthesis or cell-cycle re-entry can accompany polyploidization or multinucleation rather than the production of two daughter cells. [5]

Stronger evidence combines cell-type identification with markers or imaging of mitosis and cytokinesis, direct cell counts, clonal analysis, or genetic tracing, followed by evidence that daughter cells mature and persist. Even then, new cell production addresses only one part of regeneration; integration into organized, functional tissue remains a separate question. [3] [5]

Molecular Readouts Need Anatomical Context

Transcriptomic, proteomic, and chromatin assays can reveal injury-responsive cell states and regulatory programmes. Single-cell methods can separate signals from different cell populations that would be mixed in bulk tissue. These measurements are valuable for mechanism, but an expression signature is evidence of a state or pathway, not direct evidence that a tissue has been rebuilt. [1] [9]

Spatial validation helps connect a molecular change to the injury border, regenerated region, or a particular cell type. Perturbation experiments can then test whether the pathway is required or sufficient within that model, while structural and functional assays determine whether the molecular response has a meaningful tissue-level consequence. [1] [9]

Function, Durability, and Alternative Explanations

Functional endpoints should match the organ and model: examples include mechanical strength for bone, force production for muscle, pumping or electrical performance for heart, and locomotor tasks after spinal injury. Validated behavioural scales can detect graded recovery, but strain, injury severity, training, and observer reliability can influence the result. [4] [8]

Functional improvement does not identify its mechanism. Surviving tissue may compensate, inflammation may fall, a scar may stabilize the organ, or neural circuits may adapt without anatomical regeneration. Pairing functional results with structural and lineage evidence helps distinguish these possibilities. Longer follow-up also tests whether benefit persists after an early injury response has resolved. [2] [4] [5]

Controls, Time Courses, and Study Design

Injury-only controls estimate spontaneous recovery, sham procedures separate injury effects from the procedure itself, and uninjured tissue provides a reference for normal architecture or function. Several time points can distinguish a transient early response from tissue formation, maturation, and persistence. Because regenerative responses are context-dependent, species, strain, sex, age, injury method, severity, and timing should be reported and considered when interpreting generalizability. [1] [6] [8]

Random allocation reduces systematic group differences, while blinded collection or scoring limits the influence of treatment knowledge on subjective decisions. Prespecified inclusion and exclusion criteria, sample-size justification, complete accounting of animals, and transparent statistical methods make the resulting claim easier to audit and reproduce. These principles are central to ARRIVE 2.0 and broader guidance on preclinical rigor. [6] [7]

Evidence Quality and Interpretation

Confidence is higher when independently informative measurements converge: for example, lineage evidence shows new cells, three-dimensional or histological analysis shows restored organization, and a validated assay shows durable function. Confidence also rises when the study has adequate controls and the principal result is reproduced in an independent experiment or relevant second model. [3] [4] [7]

Confidence is lower when “regeneration” rests on a single surrogate, one late image, an unblinded ordinal score, or a molecular marker without evidence of tissue replacement. No universal assay panel applies to every organ, because the necessary cell types, spatial organization, and functions differ among tissues and species. [1] [2] [5]

What This Does Not Mean

It does not mean molecular or proliferation markers are uninformative; they answer narrower questions than complete tissue regeneration. [1] [5]
It does not mean every experiment must use every available assay; measurements should match the stated claim and model. [4] [6]
It does not mean functional recovery proves anatomical restoration; compensation and repair can also improve performance. [2] [8]
It does not mean lineage tracing is assumption-free; labelling specificity, efficiency, timing, and reporter behaviour require validation. [3]

Practical Interpretation Examples

If Ki-67 or EdU increases: this supports greater cell-cycle activity or DNA synthesis, but completed division, cell identity, persistence, and integration still need to be established. [5]
If a defect becomes smaller: this shows filling or remodelling, but composition, organization, mechanics, and comparison with native tissue determine whether the result represents regeneration or repair. [2] [4]
If function improves without structural change: the result may still be biologically important, but it does not by itself show that lost tissue was replaced. [4] [8]

Summary

Measuring regeneration requires a claim-specific combination of evidence. Structural assays show what formed, lineage and cell-division methods address where cells came from, molecular assays identify active programmes, and functional tests ask whether the system works. Time courses, controls, and rigorous study design determine whether these observations support durable regeneration rather than transient activation, repair, or compensation. [1] [3] [6]

References

Goldman, J. A., Poss, K. D. (2020). “Gene regulatory programmes of tissue regeneration.” Nature Reviews Genetics. https://www.nature.com/articles/s41576-020-0239-7
Wells, J. M., Watt, F. M. (2018). “Diverse mechanisms for endogenous regeneration and repair in mammalian organs.” Nature. https://www.nature.com/articles/s41586-018-0073-7
Romagnani, P., Rinkevich, Y., Dekel, B. (2015). “The use of lineage tracing to study kidney injury and regeneration.” Nature Reviews Nephrology. https://www.nature.com/articles/nrneph.2015.67
Trachtenberg, J. E., Vo, T. N., Mikos, A. G. (2015). “Pre-clinical characterization of tissue engineering constructs for bone and cartilage regeneration.” Annals of Biomedical Engineering. https://pmc.ncbi.nlm.nih.gov/articles/PMC4380647/
Bois, A., et al. (2025). “Revitalizing the heart: strategies and tools for cardiomyocyte regeneration post-myocardial infarction.” npj Regenerative Medicine. https://www.nature.com/articles/s41536-025-00394-2
Percie du Sert, N., et al. (2020). “The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research.” PLOS Biology. https://doi.org/10.1371/journal.pbio.3000410
Huang, W., Percie du Sert, N., Vollert, J., Rice, A. S. C. (2020). “General principles of preclinical study design.” Handbook of Experimental Pharmacology. https://pmc.ncbi.nlm.nih.gov/articles/PMC7610693/
Basso, D. M., et al. (2006). “Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains.” Journal of Neurotrauma. https://pubmed.ncbi.nlm.nih.gov/16689667/
Wagner, D. E., Klein, A. M. (2020). “Lineage tracing meets single-cell omics: opportunities and challenges.” Nature Reviews Genetics. https://www.nature.com/articles/s41576-020-0223-2

Educational Disclaimer

This content is provided for educational purposes only and does not constitute medical advice.